Natera Inc (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 559 Shares

Natera Inc (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 559 shares of the company’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $33.53, for a total value of $18,743.27. Following the sale, the chief executive officer now directly owns 13,813 shares of the company’s stock, valued at $463,149.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

  • On Friday, September 20th, Steven Leonard Chapman sold 9,424 shares of Natera stock. The shares were sold at an average price of $33.19, for a total value of $312,782.56.
  • On Tuesday, September 10th, Steven Leonard Chapman sold 1,155 shares of Natera stock. The shares were sold at an average price of $29.50, for a total value of $34,072.50.
  • On Friday, August 9th, Steven Leonard Chapman sold 98,996 shares of Natera stock. The shares were sold at an average price of $33.00, for a total value of $3,266,868.00.

Natera stock traded up $0.88 during mid-day trading on Tuesday, hitting $34.89. The company’s stock had a trading volume of 518,845 shares, compared to its average volume of 678,458. The firm’s 50 day moving average is $31.27 and its 200 day moving average is $24.69. The company has a market cap of $2.39 billion, a PE ratio of -16.23 and a beta of 1.42. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.54 and a quick ratio of 2.42. Natera Inc has a 52-week low of $11.08 and a 52-week high of $34.95.



Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, August 7th. The medical research company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.09. The firm had revenue of $74.36 million during the quarter, compared to the consensus estimate of $66.77 million. Natera had a negative return on equity of 273.92% and a negative net margin of 46.78%. The business’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.62) EPS. As a group, analysts forecast that Natera Inc will post -2.1 EPS for the current year.

A number of institutional investors have recently made changes to their positions in the stock. US Bancorp DE lifted its stake in Natera by 575.2% in the 2nd quarter. US Bancorp DE now owns 3,099 shares of the medical research company’s stock worth $86,000 after acquiring an additional 2,640 shares in the last quarter. Focused Wealth Management Inc purchased a new stake in Natera in the 2nd quarter worth about $83,000. State Board of Administration of Florida Retirement System raised its stake in shares of Natera by 37.2% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 15,755 shares of the medical research company’s stock worth $435,000 after purchasing an additional 4,270 shares in the last quarter. Bank of Montreal Can purchased a new stake in shares of Natera during the 2nd quarter worth about $129,000. Finally, Meeder Asset Management Inc. raised its stake in shares of Natera by 134.3% during the 2nd quarter. Meeder Asset Management Inc. now owns 8,958 shares of the medical research company’s stock worth $248,000 after purchasing an additional 5,135 shares in the last quarter. 94.95% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently commented on the company. Zacks Investment Research raised Natera from a “sell” rating to a “hold” rating in a report on Friday, August 9th. Craig Hallum upped their target price on Natera from $29.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Piper Jaffray Companies upped their target price on Natera from $32.00 to $45.00 and gave the company an “overweight” rating in a report on Tuesday. Canaccord Genuity reaffirmed a “buy” rating and set a $38.00 target price on shares of Natera in a report on Wednesday, September 11th. Finally, BidaskClub raised Natera from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 19th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $34.43.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Story: Is it Safe to Invest in Commodities?

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.